1. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. (5th May 2016) Authors: Khan, Khurum H.; Wong, Mabel; Rihawi, Karim; Bodla, Shankar; Morganstein, Daniel; Banerji, Udai; Molife, Lulama R. Journal: Oncologist Issue: Volume 21:Number 7(2016) Page Start: 855 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Hyperglycemia and Phosphatidylinositol 3‐Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. (5th May 2016) Authors: Khan, Khurum H.; Wong, Mabel; Rihawi, Karim; Bodla, Shankar; Morganstein, Daniel; Banerji, Udai; Molife, Lulama R. Journal: Oncologist Issue: Volume 21:Number 7(2016) Page Start: 855 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. (September 2017) Authors: Capelan, Marta; Roda, Desamparados; Geuna, Elena; Rihawi, Karim; Bodla, Shankar; Kaye, Stan B.; Bhosle, Jaishree; Banerji, Udai; O'Brien, Mary; de Bono, Johann S.; Popat, Sanjay; Yap, Timothy A. Journal: Lung cancer Issue: Volume 111(2017) Page Start: 6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗